Skip to content
10-Q

Quarterly Report

ArriVent BioPharma, Inc. AVBP

0001104659-26-058650

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 46.57M sh
Shares Diluted Q1 2026 · Mar 31, 2026 45.07M sh
Shares Diluted Q1 2026 · Mar 31, 2025 33.9M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$41.89M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$68.01M
Short Term Investments Q1 2026 · Mar 31, 2026 $264.28M
Short Term Investments Q1 2026 · Dec 31, 2025 $267.28M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $62.1M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $45.54M
Stockholders Equity Q1 2026 · Mar 31, 2026 $323.98M
Stockholders Equity Q1 2026 · Dec 31, 2025 $307.22M
Stockholders Equity Q1 2026 · Mar 31, 2025 $202.54M
Stockholders Equity Q1 2026 · Dec 31, 2024 $257.65M
Current Liabilities Q1 2026 · Mar 31, 2026 $25M
Current Liabilities Q1 2026 · Dec 31, 2025 $25.95M
Total Liabilities Q1 2026 · Mar 31, 2026 $25.32M
Total Liabilities Q1 2026 · Dec 31, 2025 $25.95M
Current Assets Q1 2026 · Mar 31, 2026 $348.7M
Current Assets Q1 2026 · Dec 31, 2025 $332.9M
Total Assets Q1 2026 · Mar 31, 2026 $349.3M
Total Assets Q1 2026 · Dec 31, 2025 $333.17M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.96
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.90
Eps Basic Q1 2026 · Mar 31, 2026 −$0.96
Eps Basic Q1 2026 · Mar 31, 2025 −$1.90
Sga Expense Q1 2026 · Mar 31, 2026 $8.49M
Sga Expense Q1 2026 · Mar 31, 2025 $5.48M
Rd Expense Q1 2026 · Mar 31, 2026 $37.62M
Rd Expense Q1 2026 · Mar 31, 2025 $61.29M
Net Income Q1 2026 · Mar 31, 2026 −$43.32M
Net Income Q1 2026 · Mar 31, 2025 −$64.39M
Operating Income Q1 2026 · Mar 31, 2026 −$46.11M
Operating Income Q1 2026 · Mar 31, 2025 −$66.77M